Flibanserin (code name BIMT-17; proposed trade name Girosa) is a drug being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD). Development by Boehringer Ingelheim was halted in October 2010 following a negative report by the U.S. Food and Drug Administration.
This page contains content from the copyrighted Wikipedia article "Flibanserin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
